Skip to content

MoLO study - Evaluation of cost/efficacy ratio of monotherapy with lopinavir/ritonavir versus standard in patients treated with protesi inhibotors in virologic suppressison. - ND

MoLO study - Evaluation of cost/efficacy ratio of monotherapy with lopinavir/ritonavir versus standard in patients treated with protesi inhibotors in virologic suppressison. - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-007765-23-IT
Enrollment
Unknown
Registered
2009-12-11
Start date
2010-03-24
Completion date
Unknown
Last updated
2013-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic HIV infection MedDRA version: 12.1 Level: LLT Classification code 10008922 Term: Chronic infection with HIV

Interventions

Trade Name: KALETRA Pharmaceutical Form: Film-coated tablet INN or Proposed INN: LOPINAVIR CAS Number: 192725-17-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2

Sponsors

SIMIT sezione Regione Lombardia
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: age over or equal to 18; HIV infection in stable treatment con PI and nucleosidic analogs from at least 6 months; HIV-RNA=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: nadir linfocyte CD4+ <50/?l, previous failure to PI etc.

Design outcomes

Primary

MeasureTime frame
Main Objective: to evaluate the reduction of annual cost for the patient treated with a monotherapy with lopinavir/r vs standard care (SOC,combination of 3 different drugs);Secondary Objective: evaluation and comparison between the 2 arms of the study: incidence of virologic failure in the period of 3 years; virologic response to a subsequent therapy in case of virologic failure; distribution during the time of virologic failures; etc..;Primary end point(s): average of annual cost/benefit in patients treated with monotherapy vs SC.

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026